Sonus Pharmaceuticals to Present at Lazard Capital Markets Third Annual Life Sciences Conference, November 29
21 Noviembre 2006 - 4:30PM
Business Wire
Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that
Michael A. Martino, President and Chief Executive Officer, will
present at the Lazard Capital Markets Third Annual Life Sciences
Conference at 2:00 P.M. Eastern Time on Wednesday, November 29, in
New York City. The Company�s presentation will be broadcast live
and archived on the Sonus web site at
www.sonuspharma.com/events.html. Sonus� lead oncology product
candidate is TOCOSOL� Paclitaxel, a new formulation of the widely
prescribed anti-cancer drug, paclitaxel. TOCOSOL Paclitaxel is
currently in a Phase 3 pivotal trial for the potential treatment of
metastatic breast cancer. The trial is being conducted under a
Special Protocol Assessment with the U.S. Food and Drug
Administration. Patient enrollment in the Phase 3 trial was
completed in November 2006. The New Drug Application submission for
TOCOSOL Paclitaxel is targeted for the end of 2007. About Sonus
Pharmaceuticals, Inc. Headquartered near Seattle, Sonus
Pharmaceuticals is focused on the development of cancer drugs that
are designed to provide improved efficacy, safety and tolerability,
and are more convenient to use. In addition to the continuing
advancement of TOCOSOL Paclitaxel, Sonus initiated the Phase 1
clinical development program for its second product candidate,
TOCOSOL Camptothecin, in September 2006. TOCOSOL Camptothecin is a
new entry in the same drug class as the approved camptothecin
analogs, irinotecan and topotecan. Preclinical data suggest that
TOCOSOL Camptothecin may be more efficacious and better tolerated
than irinotecan. For additional information on Sonus, including
news releases, please visit www.sonuspharma.com. Safe Harbor
Certain statements made in this press release are forward-looking
such as those, among others, relating to the development, safety
and efficacy of therapeutic drugs and potential applications for
these products. As discussed in Sonus Pharmaceuticals� filings with
the Securities and Exchange Commission, including its Annual Report
on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the
third quarter of 2006, actual results could differ materially from
those projected in the forward-looking statements as a result of
the following factors, among others: the Company�s products will
require extensive clinical testing and approval by regulatory
authorities; such approvals are lengthy and expensive and may never
occur; risks that the Company will not be able to complete the
Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical
studies with TOCOSOL Paclitaxel will be delayed or will not be
successful; risks that the FDA may not approve the TOCOSOL
Paclitaxel New Drug Application; risks that the Phase 1 clinical
trial for TOCOSOL Camptothecin will not be successful; risks of
successful development of therapeutic drugs; and risks that the
Company may not be successful in obtaining funding from third
parties or completing a financing necessary to support the costs
and expenses of clinical studies as well as research and
development activities. The Company undertakes no obligation to
update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof.
Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that
Michael A. Martino, President and Chief Executive Officer, will
present at the Lazard Capital Markets Third Annual Life Sciences
Conference at 2:00 P.M. Eastern Time on Wednesday, November 29, in
New York City. The Company's presentation will be broadcast live
and archived on the Sonus web site at
www.sonuspharma.com/events.html. Sonus' lead oncology product
candidate is TOCOSOL(R) Paclitaxel, a new formulation of the widely
prescribed anti-cancer drug, paclitaxel. TOCOSOL Paclitaxel is
currently in a Phase 3 pivotal trial for the potential treatment of
metastatic breast cancer. The trial is being conducted under a
Special Protocol Assessment with the U.S. Food and Drug
Administration. Patient enrollment in the Phase 3 trial was
completed in November 2006. The New Drug Application submission for
TOCOSOL Paclitaxel is targeted for the end of 2007. About Sonus
Pharmaceuticals, Inc. Headquartered near Seattle, Sonus
Pharmaceuticals is focused on the development of cancer drugs that
are designed to provide improved efficacy, safety and tolerability,
and are more convenient to use. In addition to the continuing
advancement of TOCOSOL Paclitaxel, Sonus initiated the Phase 1
clinical development program for its second product candidate,
TOCOSOL Camptothecin, in September 2006. TOCOSOL Camptothecin is a
new entry in the same drug class as the approved camptothecin
analogs, irinotecan and topotecan. Preclinical data suggest that
TOCOSOL Camptothecin may be more efficacious and better tolerated
than irinotecan. For additional information on Sonus, including
news releases, please visit www.sonuspharma.com. Safe Harbor
Certain statements made in this press release are forward-looking
such as those, among others, relating to the development, safety
and efficacy of therapeutic drugs and potential applications for
these products. As discussed in Sonus Pharmaceuticals' filings with
the Securities and Exchange Commission, including its Annual Report
on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the
third quarter of 2006, actual results could differ materially from
those projected in the forward-looking statements as a result of
the following factors, among others: the Company's products will
require extensive clinical testing and approval by regulatory
authorities; such approvals are lengthy and expensive and may never
occur; risks that the Company will not be able to complete the
Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical
studies with TOCOSOL Paclitaxel will be delayed or will not be
successful; risks that the FDA may not approve the TOCOSOL
Paclitaxel New Drug Application; risks that the Phase 1 clinical
trial for TOCOSOL Camptothecin will not be successful; risks of
successful development of therapeutic drugs; and risks that the
Company may not be successful in obtaining funding from third
parties or completing a financing necessary to support the costs
and expenses of clinical studies as well as research and
development activities. The Company undertakes no obligation to
update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof.
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals, Inc. Artículos de Noticias